Precigen (PGEN) Set to Post Earnings on Wednesday

Precigen (NASDAQ:PGEN) is expected to post its Q3 2026 results after the market closes on Wednesday, November 4th. Analysts expect Precigen to announce earnings of $0.06 per share and revenue of $71.56 million for the quarter. Investors may review the information on the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Wednesday, November 4, 2026 at 4:30 PM ET.

Precigen (NASDAQ:PGEN) last announced its quarterly earnings results on Tuesday, August 4th. The biotechnology company reported $0.05 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.01) by $0.06. The firm had revenue of $54.98 million for the quarter, compared to analysts’ expectations of $27.98 million. Precigen had a positive return on equity of 423.75% and a negative net margin of 183.98%. Precigen’s revenue for the quarter was up 6322.7% compared to the same quarter last year. On average, analysts expect Precigen to post $0.23 EPS for the current fiscal year and $0.72 EPS for the next fiscal year.

Precigen Price Performance

Shares of NASDAQ PGEN traded up $0.01 during midday trading on Tuesday, reaching $5.16. 4,527,392 shares of the company traded hands, compared to its average volume of 4,789,916. Precigen has a 12 month low of $3.04 and a 12 month high of $8.98. The company has a debt-to-equity ratio of 2.15, a quick ratio of 3.89 and a current ratio of 4.58. The stock’s 50-day simple moving average is $7.18 and its 200-day simple moving average is $5.28. The firm has a market cap of $1.84 billion, a PE ratio of -4.96 and a beta of 1.01.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on PGEN. Weiss Ratings reissued a “sell (d-)” rating on shares of Precigen in a report on Thursday, October 15th. Wall Street Zen lowered shares of Precigen from a “strong-buy” rating to a “buy” rating in a research report on Saturday. Zacks Research cut shares of Precigen from a “strong-buy” rating to a “hold” rating in a research note on Monday, October 5th. B. Riley Financial initiated coverage on shares of Precigen in a report on Friday, September 25th. They set a “buy” rating and a $12.00 price objective for the company. Finally, HC Wainwright boosted their price objective on Precigen from $14.00 to $18.00 and gave the stock a “buy” rating in a research note on Wednesday, August 5th. Four analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Precigen currently has a consensus rating of “Moderate Buy” and a consensus price target of $13.67.

Insider Buying and Selling

In other news, COO Rutul R. Shah sold 34,658 shares of the company’s stock in a transaction on Friday, August 21st. The stock was sold at an average price of $7.50, for a total transaction of $259,935.00. Following the transaction, the chief operating officer owned 465,012 shares of the company’s stock, valued at $3,487,590. This represents a 6.94% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Jeffrey B. Kindler sold 185,000 shares of the firm’s stock in a transaction dated Wednesday, August 26th. The shares were sold at an average price of $7.44, for a total value of $1,376,400.00. Following the completion of the transaction, the director owned 17,100 shares in the company, valued at approximately $127,224. This represents a 91.54% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 267,739 shares of company stock worth $1,975,990 over the last quarter. 41.40% of the stock is owned by company insiders.

Precigen Company Profile

Precigen, Inc is a clinical-stage biotechnology company focused on developing gene and cell therapies for cancer and serious diseases. The company uses its proprietary UltraCAR-T, AdenoVerse, and other gene-engineering platforms to design potential treatments intended to improve the targeting, persistence, and manufacturing of therapeutic cells and genetic medicines.

Precigen’s pipeline has included PRGN-2012, an investigational immunotherapy based on a gorilla adenovector for recurrent respiratory papillomatosis, as well as PRGN-2001, an investigational HPV-targeted immunotherapy.